Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study

[1]  S. Gulati,et al.  Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study. , 2020, The Lancet. Oncology.

[2]  P. Fasching,et al.  Real-world clinical effectiveness and safety of olaparib monotherapy in HER2-negative gBRCA-mutated metastatic breast cancer: Phase IIIb LUCY interim analysis. , 2020 .

[3]  E. Winer,et al.  TBCRC 048: A phase II study of olaparib monotherapy in metastatic breast cancer patients with germline or somatic mutations in DNA damage response (DDR) pathway genes (Olaparib Expanded). , 2020 .

[4]  S. Friedman,et al.  NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020. , 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

[5]  Amy M. Sitapati,et al.  Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. , 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

[6]  Angela Mariotto,et al.  Genetic Testing and Results in a Population-Based Cohort of Breast Cancer Patients and Ovarian Cancer Patients. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[8]  W. Eiermann,et al.  Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation , 2018, The New England journal of medicine.

[9]  John L Marshall,et al.  Prevalence of Homologous Recombination-Related Gene Mutations Across Multiple Cancer Types. , 2018, JCO precision oncology.

[10]  E. Kass,et al.  Homology-Directed Repair and the Role of BRCA1, BRCA2, and Related Proteins in Genome Integrity and Cancer. , 2018, Annual review of cancer biology.

[11]  Steven N. Hart,et al.  Abstract PD1-02: Cancer predisposition genes in metastatic breast cancer – Association with metastatic pattern, prognosis, patient and tumor characteristics , 2018 .

[12]  Jun Wang,et al.  Analysis of BRCA1/2 mutation spectrum and prevalence in unselected Chinese breast cancer patients by next-generation sequencing , 2017, Journal of Cancer Research and Clinical Oncology.

[13]  M. Robson,et al.  Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation , 2017, The New England journal of medicine.

[14]  Jian Zhang,et al.  Efficacy and safety of everolimus in Chinese metastatic HR positive, HER2 negative breast cancer patients: a real-world retrospective study , 2017, Oncotarget.

[15]  S. Zhang,et al.  Efficacy and safety of everolimus in Chinese metastatic HR positive, HER2 negative breast cancer patients: a real-world retrospective study , 2017, Oncotarget.

[16]  A. Giordano,et al.  A Real‐World Multicentre Retrospective Study of Paclitaxel‐Bevacizumab and Maintenance Therapy as First‐Line for HER2‐Negative Metastatic Breast Cancer , 2016, Journal of cellular physiology.

[17]  P. Kellokumpu-Lehtinen,et al.  Bevacizumab Combined with Docetaxel or Paclitaxel as First-line Treatment of HER2-negative Metastatic Breast Cancer. , 2016, Anticancer research.

[18]  M. Moore,et al.  Clinical, Histopathological and Molecular Characteristics of Metastatic Breast Cancer in North-Eastern Kazakhstan: a 10 Year Retrospective Study , 2016, Asian Pacific journal of cancer prevention : APJCP.

[19]  Y. Drew,et al.  Homologous recombination deficiency and ovarian cancer. , 2016, European journal of cancer.

[20]  T. Aas,et al.  BRCA1/2 testing in newly diagnosed breast and ovarian cancer patients without prior genetic counselling: the DNA-BONus study , 2015, European Journal of Human Genetics.

[21]  M. O’Connor,et al.  Targeting the DNA Damage Response in Cancer. , 2015, Molecular cell.

[22]  S. Narod,et al.  Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from Peru , 2015, Clinical genetics.

[23]  H Tesch,et al.  Biomarkers in Patients with Metastatic Breast Cancer and the PRAEGNANT Study Network. , 2015, Geburtshilfe und Frauenheilkunde.

[24]  C Sotiriou,et al.  The AURORA initiative for metastatic breast cancer , 2014, British Journal of Cancer.

[25]  A. Godwin,et al.  Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing , 2014, Breast Cancer Research and Treatment.

[26]  S. Narod,et al.  Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from medellín, Colombia , 2014, Hereditary Cancer in Clinical Practice.

[27]  G. Hortobagyi,et al.  Outcome of metastatic breast cancer in selected women with or without deleterious BRCA mutations , 2013, Clinical & Experimental Metastasis.

[28]  P. Møller,et al.  The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers , 2012, British Journal of Cancer.

[29]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[30]  D. Brizel,et al.  National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology , 2012 .

[31]  Sofia Khan,et al.  Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations , 2012, Familial Cancer.

[32]  G. Hortobagyi,et al.  Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  A. Monteiro,et al.  Prevalence of BRCA1 and BRCA2 mutations in breast cancer patients from Brazil , 2007, Breast Cancer Research and Treatment.

[34]  Giske Ursin,et al.  Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years. , 2006, Cancer research.

[35]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..